Dacomitinib Improves Survival in Non-Small-Cell Lung Cancer Dacomitinib Improves Survival in Non-Small-Cell Lung Cancer

Dacomitinib as first-line treatment improves progression-free survival, compared with gefitinib, in patients with EGFR-mutation-positive non-small-cell lung cancer (NSCLC), according to results from the international ARCHER 1050 trial.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news